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Introduction {#sec005}
============

Uncontrolled chronic hepatitis C virus (HCV) infection eventually leads to liver cirrhosis or liver cancer and results in significant morbidity and mortality \[[@pone.0237582.ref001]\]. It has been estimated that 130--170 million people are infected with HCV, resulting in a global prevalence of 2%--3% \[[@pone.0237582.ref002], [@pone.0237582.ref003]\]. Over the past two decades, interferon-based therapy has been the standard treatment for HCV infection. Sustained virological response (SVR) rates in patients with HCV infection range from 60%--80% following six months of peg-interferon-based therapy \[[@pone.0237582.ref004], [@pone.0237582.ref005]\]. Recently, HCV treatment was revolutionised with the introduction of direct-acting antiviral (DAA) therapy. High SVR rates (\> 90%) and good treatment tolerance have been reported for interferon-free regimens. These new agents have been reimbursed by the Taiwanese health care system since 2017, and the government has set the goal of obtaining an 80%-treatment coverage rate with DAAs by 2025 \[[@pone.0237582.ref006]--[@pone.0237582.ref008]\]. In the past, treatment success for HCV infection in patients with chronic kidney disease lagged behind that of the general population \[[@pone.0237582.ref009]\]. Today, it is possible to cure most HCV-infected patients with oral DAAs.

Glecaprevir (GLE) is a NS3 protease inhibitor, and pibrentasvir (PIB) is a NS5A inhibitor. Since August 2018, glecaprevir--pibrentasvir (GLE/PIB) has been reimbursed in Taiwan for patients \[[@pone.0237582.ref001]\] with confirmed HCV viremia with no prior DAA therapy. Both GLE and PIB are excreted through the biliary tree and fecal route. There is no need for dosage adjustment for patients with renal function impairment. It is the first and only pan-genotype DAA for both patients with and without end-stage renal disease (ESRD) \[[@pone.0237582.ref002]\]. In the EXPEDITION-4 study \[[@pone.0237582.ref002]\], a high SVR rate and good safety profile were reported for patients with ESRD. Until now, real-world data on the safety and effectiveness of GLE/PIB in patients with hepatitis c infection with and without ESRD are still limited. Thus, we report our real-world experience with anti-HCV therapy with GLE/PIB in our institution.

Materials and methods {#sec006}
=====================

Materials {#sec007}
---------

This retrospective study included DAA treatment naïve patients undergoing treatment for HCV infection, who received anti-HCV therapy with GLE/PIB between August 2018 and December 2019 at Changhua Christian Hospital. The study was approved by the Changhua Christian Hospital Institutional Review Board (CCH IRB No 190814), and documentation of informed consent was waived because the study was conducted retrospectively. Medical information, including demographics, baseline medical conditions, anti-HCV treatment regimen and duration, laboratory values and information on adverse events were extracted from electronic patient records. The anti-HCV treatment response at the end of treatment was compared with that after the treatment. All procedures were carried out in accordance with relevant guidelines and regulations of the Changhua Christian hospital.

Treatment, efficacy, and safety evaluation {#sec008}
------------------------------------------

Our primary goal was to compare the treatment response in patients with and without ESRD in our institution. We used ART HCV assays (RealTime HCV and HCV Genotype II, Abbott Molecular, Abbott Park, IL, USA) to quantify HCV RNA concentrations and genotyping. End-of-treatment viral response (ETVR) was defined as an HCV RNA level \< the lower limit of quantification (LLOQ) when completing the treatment course. A SVR was defined as an HCV RNA level \< LLOQ at 12 weeks after the last medication. GLI/PIB was reimbursed by the National Health Insurance of Taiwan since Aug 2018 for patients with confirmed HCV viremia without prior use of DAA. The treatment period was 8 weeks for patients without liver cirrhosis and 12 weeks for patients with compensated liver cirrhosis. Virological treatment failure was defined as either (a) non-response: HCV was detected during and at end of treatment; or (b) relapse: HCV was undetectable at the end of treatment but detectable during the follow-up period. The diagnosis of cirrhosis was established by liver biopsy, observing stage-4 fibrosis or by ultrasound-based findings of cirrhosis or the presence of oesophageal varices during endoscopy. Two endpoints for SVR were evaluated. The intention-to-treat group (ITT) included patients receiving at least one dose of GLE/PIB and the per-protocol group (PP), established by excluding patients due to non-virological failure. The rate of premature treatment discontinuation was also analysed. ESRD was defined as chronic kidney disease stage 5 with dialysis \[[@pone.0237582.ref010]\] in the present study.

Statistical analyses {#sec009}
--------------------

Statistical analyses were performed using the SPSS software version 18.0 and Medcalc software version 19.3. Differences between the two groups were considered statistically significant when probability (P) values were \< 0.05.

Results {#sec010}
=======

General characteristics of patients with HCV infection {#sec011}
------------------------------------------------------

A total of 235 patients with HCV infection received GLE/PIB-based anti-HCV therapy during the study period ([Fig 1](#pone.0237582.g001){ref-type="fig"}). Forty-four of these patients had ESRD with haemodialysis (n = 40) or peritoneal dialysis (n = 4). Most patients were female (52%) with a median age of 60 years. The ESRD group had a higher proportion of interferon treatment naïve patients. Liver cirrhosis was present in 51 patients (22%). The most common HCV genotype observed was type 1 (43%), followed by type 2 (41%), type 3 (8%) and others (8%). Five percent of the patients were co-infected with hepatitis B. Three fatalities were observed during (n = 2) and after (n = 1) the treatment period. All the deaths were judged not to be related to the treatment. Premature treatment termination was observed for one patient due to side effects (skin itching). One patient was lost to follow-up after achieving end-of-treatment response. Six patients in the non-ESRD group without ETVR achieved SVR after completed treatment. Three patients in the non-ESRD group with ETVR exhibited viral relapse 12 weeks after the treatment. One of the patients with drug abuse and HIV co-infection had a different HCV genotype at the time of virological relapse, and so re-infection was suspected. The overall ITT SVR rate was 96.6%, and the PP SVR rate was 98.7%. Patient characteristics are summarised in [Table 1](#pone.0237582.t001){ref-type="table"} and [Fig 1](#pone.0237582.g001){ref-type="fig"}.

![Algorithm of patient inclusion.](pone.0237582.g001){#pone.0237582.g001}

10.1371/journal.pone.0237582.t001

###### Patient characteristics at baseline.

![](pone.0237582.t001){#pone.0237582.t001g}

  Characteristic                                         All patients (N = 235)   Non-ESRD (N = 191)   ESRD (N = 44)         P value
  ------------------------------------------------------ ------------------------ -------------------- --------------------- ---------
  Male, n (%)                                            112 (48)                 86 (45)              26 (59)               0.092
  Age (in years), mean ± SD                              60 ± 12.5                58.3 ± 12            67.6 ± 12.1           \<0.001
  FIB-4, median (IQR)                                    1.89 (1.29--2.78)        1.81(1.25--2.6)      2.33(1.71--3.15)      0.007
  Cirrhosis, n (%)                                       51 (22)                  37 (19)              14 (32)               0.071
  Hepatitis B, n (%)                                     11 (5)                   9 (5)                2 (5)                 1.000
  HIV, n (%)                                             5 (2)                    5 (3)                0                     0.587
  Diabetes, n (%)                                        32 (14)                  23 (12)              9 (20)                0.142
  Hypertension, n (%)                                    42 (18)                  29 (15)              13 (30)               0.025
  Stroke, n (%)                                          6 (3)                    5 (3)                1 (2)                 1.000
  Cancer, n (%)                                          14 (6)                   11 (6)               3 (7)                 0.730
  HCV RNA (log IU/mL), median (IQR)                      5.74 (4.82--6.35)        5.9 (4.98--6.41)     5.33 (4.04--6.1)      0.005
  HCVgenotype, n (%)                                                                                                         
  Type 1[^a^](#t001fn002){ref-type="table-fn"}           102 (43)                 78 (41)              24 (55)               0.137
  Type 2[^b^](#t001fn003){ref-type="table-fn"}           97 (41)                  80 (42)              17 (39)               0.822
  Type 3                                                 18 (8)                   17 (9)               1 (2)                 0.209
  Type 4                                                 1 (0.4)                  1 (0.5)              0                     1.000
  Type 6                                                 13 (6)                   11 (6)               2 (5)                 1.000
  Mixed genotype[^c^](#t001fn004){ref-type="table-fn"}   4 (2)                    4 (2)                0                     1.000
  Prior Therapy, n (%)                                                                                                       
  Interferon naïve                                       199 (84.7)               157 (82.2)           42 (95.5)             0.028
  Interferon relapse                                     3 (1.3)                  3 (1.6)              0 (0)                 1
  Interferon failure                                     33 (14.1)                31 (16.2)            2 (4.5)               0.045
  Complete Treatment, n/N (%)                                                                                                
  8 week course                                          181/184 (98)             152/154 (99)         29/30 (97)            0.416
  12 week course                                         46/51 (90)               33/37 (89)           13/14 (93)            1.000
  Height, cm, mean± SD                                   160.1 ± 8.5              160.1 ± 8.3          160.5 ± 9.3           0.760
  Weight, kg, median (IQR)                               60(53--69.4)             59.7(52--70)         60.3(53--66)          0.779
  BMI, kg/m^2^, median (IQR)                             23.3(21.3--26)           23.32(21.3--25.97)   23.325(20.7--26.21)   0.924
  Creatinine, mg/dL, median (IQR)                        0.87(0.65--1.46)         0.78(0.63--1.01)     8.1(7.09--10.23)      \<0.001
  GOT (AST), U/L, median (IQR)                           37(27--53)               38(29--58)           31(21.5--40)          \<0.001
  GPT (ALT), U/L, median (IQR)                           40(25--61)               42(27--69)           25.5(20--39)          \<0.001
  Platelet,10^3^/μL, median (IQR)                        193(151--236)            199(153--239)        169.5(131--206.5)     \<0.001
  INR, median (IQR)                                      0.94(0.89--0.99)         0.94(0.89--0.99)     0.91(0.89--0.97)      0.209
  Bilirubin, mg/dL, median (IQR)                         0.67(0.47--0.88)         0.7(0.5--0.9)        0.56(0.435--0.695)    \<0.001
  Albumin, g/dL, median (IQR)                            4 (3.7--4.3)             4.1(3.9--4.3)        3.45(3.1--3.65)       \<0.001
  Hemoglobin, g/dL, median (IQR)                         13.5(11.4--14.7)         13.9(12.7--15)       10.55(9.3--11.7)      \<0.001

Data are expressed as n (%), median (interquartile range \\IQR\]), or mean ± standard deviation. Categorical variables were compared using the χ^2^ test or Fisher's exact test, as applicable; continuous variables were compared using Student's t test or Mann--Whitney *U* test. P values \<0.05 were considered statistically significant.

^a^ HCV genotype 1, including 1, 1a, 1b.

^b^ HCV genotype 2, including 2, 2a, 2b

^c^ Mixed genotype, including 1b+2, 1b+3, 1 or 6

Comparison of patients with/without ESRD {#sec012}
----------------------------------------

The clinical features and treatment responses of patients with and without ESRD are displayed in [Table 2](#pone.0237582.t002){ref-type="table"}. Patients with ESRD were older than those without ESRD (67.6 years *vs* 58.3 years, P \< 0.001). Lower platelet counts, levels of haemoglobin, albumin, GOT/GPT, and HCV viremia were observed in the ESRD group at baseline. Patients with ESRD had a higher Fibrosis-4 (FIB-4) index than those without ESRD and more patients with ESRD had hypertension. The distribution of HCV genotypes did not differ between the two groups. Both patient groups achieved similarly high rates of EVTR and SVR.

10.1371/journal.pone.0237582.t002

###### On-treatment and off-therapy virological responses.

![](pone.0237582.t002){#pone.0237582.t002g}

  HCV RNA \< LLOQ[^a^](#t002fn003){ref-type="table-fn"}   All patients (N = 235)   Non-ESRD (N = 191)   ESRD (N = 44)    P value                                  
  ------------------------------------------------------- ------------------------ -------------------- ---------------- ------------ -------------- ------------ -------
  **End of Treatment Response (ETVR)**                                                                                                                            
  Intention to Treat                                      226/235 (96.2)           92.9--98.2           184/191 (96.3)   92.6--98.5   42/44 (95.5)   84.5--99.4   0.677
  Per Protocol Analysis                                   226/232 (97.4)           94.5--99.0           184/190 (96.8)   93.3--98.8   42/42 (100)    91.6--100    0.595
  **Sustained Response (SVR)**                                                                                                                                    
  Intention to Treat                                      227/235 (96.6)           93.4--98.5           185/191 (96.9)   93.3--98.8   42/44 (95.5)   84.5--99.4   0.646
  Per Protocol Analysis                                   227/230 (98.7)           96.2--99.7           185/188 (98.4)   95.4--99.7   42/42 (100)    91.6--100    1.000
  **Reason for non-SVR, n**                                                                                                                                       
  Death                                                   3                        2                    1                0.465                                    
  Discontinued due to side effect                         1                        0                    1                0.187                                    
  Lost to follow-up                                       1                        1                    0                1.000                                    

Statistical analysis for one proportion was performed using the Medcalc statistical software.

Categorical variables were compared by the χ^2^ test or Fisher's exact test as applicable. P values \< 0.05 were considered statistically significant.

^a^ LLOQ, lower limit of qualification is 12 IU/mL.

Side effects of the treatment {#sec013}
-----------------------------

Pruritus is the most commonly reported side effect of GLE/PIB treatment, followed by insomnia, malaise, and abdominal discomfort ([Table 3](#pone.0237582.t003){ref-type="table"}). A significant increase in the levels of bilirubin, GOT, and GPT was observed in \<1.3% of the patients. We further analysed the time course and severity of pruritus and its impact on the SVR ([Table 4](#pone.0237582.t004){ref-type="table"}). Significantly more patients with ESRD reported pruritus during treatment compared with those without ESRD (61% *vs* 26%, P \< 0.001). Twenty-three percent of the patients with ESRD experienced grade-3 pruritus. The presence of pruritus occurred mostly during the first 4 weeks of treatment, subsequently the rate of pruritus decreased over time. One patient in the ESRD group discontinued treatment prematurely due to this side effect. The presence of pruritus did not impair the overall SVR rate of patients with and without ESRD.

10.1371/journal.pone.0237582.t003

###### Safety profile of glecaprevir--pibrentasvir therapy.

![](pone.0237582.t003){#pone.0237582.t003g}

  Adverse event, n (%)                          All patients (N = 235)   Non-ESRD (N = 191)   ESRD (N = 44)   P-values                 
  --------------------------------------------- ------------------------ -------------------- --------------- ---------- ---- -------- ---------
  Pruritus                                      77                       (32.9)               50              (19.1)     27   (62.8)   0.160
  Insomnia                                      17                       (7.2)                10              (5.2)      7    (15.9)   0.022
  Abdominal discomfort                          10                       (4.3)                9               (4.7)      1    (2.3)    0.693
  GERD                                          2                        (0.9)                2               (1.0)      0             1.000
  Malaise                                       15                       (6.4)                14              (7.3)      1    (2.3)    0.315
  Dizziness                                     8                        (3.4)                7               (3.7)      1    (2.3)    1.000
  Anorexia                                      3                        (1.3)                2               (1.0)      1    (2.3)    0.465
  Anemia[\*](#t003fn002){ref-type="table-fn"}                                                                                          
  G0                                            174                      (74.0)               164             (85.9)     10   (22.7)   \<0.001
  G1                                            35                       (14.9)               15              (7.9)      20   (45.5)   \<0.001
  G2                                            22                       (9.4)                9               (4.7)      13   (29.5)   \<0.001
  G3                                            4                        (1.7)                3               (1.6)      1    (2.3)    0.566
  Bilirubin                                                                                                                            
  1.5-3x elevation                              30                       (12.8)               26              (13.6)     4    (9.1)    0.418
  ≥3x elevation                                 3                        (1.3)                2               (1.0)      1    (2.3)    0.465
  GOT                                                                                                                                  
  3-5x elevation                                2                        (0.9)                2               (1.0)      0    \(0\)    1.000
  ≥5x elevation                                 2                        (0.9)                0                          1    (2.3)    0.187
  GPT                                                                                                                                  
  3-5x elevation                                2                        (0.9)                1               (0.5)      1    (2.3)    0.340
  ≥5x elevation                                 1                        (0.4)                2               (1.0)      0    \(0\)    1.000

Data are expressed as n/N (%). Categorical variables were compared using the χ2 test or Fisher's exact test. P values \<0.05 were considered statistically significant.

\*Grade of the side effect according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

10.1371/journal.pone.0237582.t004

###### Time course and grade of pruritus.

![](pone.0237582.t004){#pone.0237582.t004g}

  Characteristic                                                      All patients (N = 234)   Non-ESRD (N = 191)   ESRD (N = 43[^a^](#t004fn002){ref-type="table-fn"})   P value                    
  ------------------------------------------------------------------- ------------------------ -------------------- ----------------------------------------------------- --------- ------- -------- ---------
  **Grade of pruritus, n (%)**[\*](#t004fn003){ref-type="table-fn"}                                                                                                                                  
  G0                                                                  158                      \(67\)               141                                                   \(74\)    17      \(39\)   \<0.001
  G1                                                                  42                       \(18\)               31                                                    \(16\)    11      \(25\)   0.250
  G2                                                                  18                       \(8\)                12                                                    \(6\)     6       \(14\)   0.116
  G3                                                                  17                       \(7\)                7                                                     \(4\)     10      \(23\)   \<0.001
  **Treatment course of eight weeks**                                 N = 185                  N = 155              N = 30                                                                           
  Skin itch in fourth week, n (%)                                     47/185                   \(25\)               31/155                                                \(20\)    16/30   \(53\)   \<0.001
  Skin itch in eighth week, n (%)                                     11/185                   \(6\)                6/155                                                 \(4\)     5/30    \(17\)   0.018
  **Treatment course of twelve weeks**                                N = 49                   N = 36               N = 13                                                                           
  Skin itch in fourth week, n (%)                                     18/49                    \(37\)               11/36                                                 \(31\)    7/13    \(54\)   0.184
  Skin itch in eighth week, n (%)                                     10/49                    \(20\)               5/36                                                  \(14\)    5/13    \(39\)   0.104
  Skin itch in twelfth week, n (%)                                    2/49                     \(4\)                1/36                                                  \(3\)     1/13    \(8\)    0.464

Data are expressed as n/N (%). Categorical variables were compared using the χ^2^ test or Fisher's exact test. P values \<0.05 were considered statistically significant.

^a^. One patient left the study due to side effect and therefore, ESRD data are not available for this patient.

\*Grade of the side effect according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0.

Discussion {#sec014}
==========

In this single-centre cohort study of HCV-infected patients receiving GLE/PIB therapy, we report an overall SVR rate of 96.6%. Our results are comparable with those observed in the clinical trial setting \[[@pone.0237582.ref002], [@pone.0237582.ref011]--[@pone.0237582.ref013]\] and other real-world reports \[[@pone.0237582.ref001], [@pone.0237582.ref007], [@pone.0237582.ref014]\], identifying GLE/PIB as a highly efficacious treatment regimen for HCV infection. Despite the several disadvantageous factors like older age and a higher prevalence of cirrhosis and pruritus-related side effects during treatment among patients with ESRD, we observed similar rates of SVR in patients with and without ESRD (95.5% *vs* 96.9%, P = 0.644).

One of the issues of treating HCV-infected patient with renal function impairment in the interferon-based therapy era was the side effects \[[@pone.0237582.ref009], [@pone.0237582.ref015], [@pone.0237582.ref016]\], and such patients are regarded as a difficult-to-treat population. Dialysis-dependent patients with active HCV infections are at increased risk of liver disease-related mortality, generally have a poor quality of life, and are at increased risk of developing cardiovascular diseases \[[@pone.0237582.ref017]\]. In addition, dialysis patients with HCV infection constitute a transmission reservoir in dialysis centres, making HCV treatment of high importance for this population. Liu et al \[[@pone.0237582.ref005]\] reported a 64% SVR rate for ESRD patients treated with interferon and ribavirin combination therapy, with a 7% withdrawal rate mainly due to treatment-related side effects. Despite the fact that untreated HCV-infected dialysis patients had a 2.62-fold increase in mortality risk compared with treated patients in a recent study from Taiwan \[[@pone.0237582.ref008], [@pone.0237582.ref009]\], only a very low proportion (6.01%) of the patients received antiviral treatment. Despite the decrease in side effects and improved SVR rates since the introduction of interferon-free DAA therapy \[[@pone.0237582.ref012], [@pone.0237582.ref014], [@pone.0237582.ref018]\], GLE/PIB is currently the only approved therapy with pan-genotypic antiviral activity for use in patients with renal function impairment. Our study revealed that GLE/PIB could with the SVR rates reaching values of 96.6% and 98.7%, as observed using ITT and PP analysis, respectively in the real-world setting, and there was no significant difference between patients with and without ESRD. The response rates in the present cohort were comparable with other clinical trials \[[@pone.0237582.ref002], [@pone.0237582.ref019], [@pone.0237582.ref020]\] and recent real-world data \[[@pone.0237582.ref007], [@pone.0237582.ref021]--[@pone.0237582.ref024]\] for patients with and without ESRD. HCV treatment experience from the real world is important because the patient population tends to be clinically more diverse and potentially less adherent to treatment compared with those included in clinical trials. A recent meta-analysis of the real-world effectiveness of GLE/PIB treatment for HCV in patients with chronic HCV infection included 12,531 adults from 18 cohorts with an overall SVR rate of 96.7% in the ITT group \[[@pone.0237582.ref021]\]. Available data on patients with renal failure is limited, and only 59 patients were included in that study. Our real-world experience is important because we included a substantial number of patients (18%) on dialysis and provides evidence that GLE/PIB can be regarded as a prioritized option for treating patients with hepatitis C regardless of renal status based on its excellent effectiveness and safety.

In terms of safety, majority of the patients (98.7%) in our study were able to complete the scheduled treatment. One patient with advanced breast cancer died of chemotherapy-related infection after achieving ETVR. Two deaths occurred in the ESRD (n = 1) and non-ESRD (n = 1) groups, and both were super-elderly, 80 and 85 years old, respectively. Both the patients died during sleep; the cause of death was suspected to be cardiogenic and related to the HCV treatment. Only one patient in the ESRD group discontinued the scheduled treatment prematurely due to the intolerable side effect of pruritus \[[@pone.0237582.ref001], [@pone.0237582.ref002]\]. We did not observe any evidence of hepatitis B flare-up in our HBV/HCV co-infected patient during the treatment. There were no cases of liver dysfunction leading to interruption of treatment or dose adjustment. The only significant side effect was pruritus, which occurred particularly among patients with ESRD in the first month of treatment. Previous clinical trials \[[@pone.0237582.ref002], [@pone.0237582.ref019]\] and real-world observations \[[@pone.0237582.ref001], [@pone.0237582.ref014], [@pone.0237582.ref022]\] have disclosed pruritus as the most frequent adverse event among patients with dialysis, and this side effect appears less frequent in other DAA regimens. Understanding the time course of this side effect is helpful to provide information to help patients overcome the side effect during treatment. After encountering the first patient with premature GLE/PIB therapy discontinuation, we provide proactive measures to educate our patients before initiating therapy and using medications such as antihistamine and/or topical agent to relieve pruritus symptom therapy initiation. Such measures have helped patients adhere +to the GLE/PIB therapy in previous studies \[[@pone.0237582.ref025], [@pone.0237582.ref026]\].

The present study has several limitations. First, there may be reporting bias with regard to the side effects because our study was retrospective, and therefore, mild side effects and the prevalence of pruritus before treatment between groups may not have been recorded in clinical practice. Because one third of our patients reported pruritus as a side effect in our initial treatment experience, we only recorded and graded this side effect; therefore, other side effects such as fatigue or change in appetite were not recorded. Second, 84% of our patients were treatment-naïve with either genotype 1 or 2, and so our study population was very homogenous. More experience is required to confirm the treatment result of GLE/PIB in patients with e.g. less common genotypes. Third, because we included patients from a single tertiary center, the treatment outcome at community hospitals or the clinics should be further confirmed. Fourth, we did not assess the on-treatment HCV RNA test because the Taiwan NHI only reimburses HCV RNA testing for SVR and ETVR. We were not able to provide viral kinetic data regarding the six patients not achieving ETVR and three patients without SVR for further analysis. Fifth, our study includes only naïve patients undergoing DAA treatment. Therefore, we cannot extrapolate the efficacy data of GLE/PIB to patients who have undergone prior failed DAA therapy.

Conclusion {#sec015}
==========

In this real-world study, we demonstrated that GLE/PIB-based therapy is highly effective for patients with and without ESRD.

Supporting information {#sec016}
======================
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Click here for additional data file.
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4\. Thank you for stating in the text of your manuscript \" documentation of informed consent was waived because the study was conducted retrospectively\". Please also add this information to your ethics statement in the online submission form.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: 1. Please mention the reason why skin itching was higher in ESRD patients. Were they actually treatment-related or present before treatment?

2\. Were all patients treated at the same department in the hospital or were ESRD patients treated at a different department?

3\. Please mention the reason for death in 3 patients.

4\. Please describe the method of HCV genotyping and HCV quantification.

5\. Was there any possible reason why HCV RNA level in ESRD patients was lower than others?

6\. Please include the treatment history in Table 1 and mention the treatment efficacy according to treatment history and treatment duration.

7\. Please mention the presence of treatment history in relapsed patients. Were the drug resistance associated variants examined in these patients?

8\. Line 52 "with oral DAAs", there is error in font style.

Reviewer \#2: In this article, the author retrospectively evaluated treatment efficacy and safety of GLE/PIB in patients with HCV and end-stage renal disease. They showed similar SVR rate and higher prevalence of pruritus among patients with ESRD.

1\) Treatment regimen should be described in more detail. The way how to decide treatment duration in Taiwan should be mentioned.

2\) The number of patients who have experienced treatment with DAAs should be described.

3\) The relationship between death and treatment should be assessed.

4\) The complications other than pruritus should be described.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237582.r002

Author response to Decision Letter 0

6 Jul 2020

Reviewer: 1

1\. Please mention the reason why skin itching was higher in ESRD patients. Were they actually treatment-related or present before treatment?

Response: Thank for your comment. As mentioned in the discussion, previous clinical trials \[2, 18\] and real-world observations \[1, 13, 21\] have disclosed pruritus as the most frequent adverse event among patients with dialysis. Itching is constantly observed as the most common side effect for GLI/PIB based therapy. Our study is the first to describe the time course change of pruritus symptom. We found the majority patients experienced pruritus during the first four week of treatment (Table 4) and we believe it should be treatment related. We added Table 3 to describe other side effects of GLI/PIB therapy in our present study.

2\. Were all patients treated at the same department in the hospital or were ESRD patients treated at a different department?

Response: Thank for your comment. In Taiwan, the use of DAA was restricted to licensed gastroenterologist and all the patients included treatment in the same department during the treatment period.

3\. Please mention the reason for death in 3 patients.

Response: Thank for your comment. Unlike clinical trial, our report of real-world experience reflects the true patients. The cause of death was discussed in the discussion section in the revised manuscript. Two deaths occurred in the ESRD (n = 1) and non-ESRD (n = 1) groups, and both were super-elderly, 80 and 85 years old, respectively. Both patients died during sleep and had no signs of other systemic disease during the last phone contact. Cardiogenic cause of death was suspected and judged not to be related to the HCV treatment. The third patient died of chemotherapy related infection.

4\. Please describe the method of HCV genotyping and HCV quantification.

Response: Thank for your comment. We used ART HCV assays (RealTime HCV and HCV Genotype II, Abbott Molecular, Abbott Park, IL, USA) to quantitatively measure HCV RNA concentrations and genotyping. We addressed this point in the revised manuscript.

5\. Was there any possible reason why HCV RNA level in ESRD patients was lower than others?

Response: Thank for your comment. Previous reports (Kaiser T, et al. Kinetics of hepatitis C viral RNA and HCV-antigen during dialysis sessions: evidence for differential viral load reduction on dialysis. J Med Virol. 2008;80(7):1195-1201 ; Fabrizi F, et al. Kinetics of hepatitis C virus load during hemodialysis: novel perspectives. J Nephrol. 2003;16(4):467-475) have described a variable reduction of HCV-RNA during hemodialysis treatment sessions. Various mechanisms have been postulated such as adsorption of HCV onto dialysis membrane, HCV escape into spent dialysate, or destruction of HCV particles during dialysis.

6\. Please include the treatment history in Table 1 and mention the treatment efficacy according to treatment history and treatment duration.

Response: Thank for your comment. We agree with your opinion that prior DAA treatment history is important to guide subsequent DAA therapy. As we mentioned efficacy and safety evaluation section, GLI/PIB was reimbursed by the National Health Insurance of Taiwan since Aug 2018 for patients with confirmed HCV viremia without prior use of DAA. Thus, there is no relevant treatment history for patients included in this analysis. We include the interferon therapy history in the revised Table 1. We will acknowledge it as our study limitation.

7\. Please mention the presence of treatment history in relapsed patients. Was the drug resistance associated variants examined in these patients?

Response: Thank for your comment. We included only DAA treatment naïve patients in this study. Drug resistance is not tested prior to Glecaprevir--Pibrentasvir therapy in this study.

8\. Line 52 "with oral DAAs", there is error in font style.

Response: Thank for your comment. We correct this error in revised manuscript.

Reviewer \#2: In this article, the author retrospectively evaluated treatment efficacy and safety of GLE/PIB in patients with HCV and end-stage renal disease. They showed similar SVR rate and higher prevalence of pruritus among patients with ESRD.

1\) Treatment regimen should be described in more detail. The way how to decide treatment duration in Taiwan should be mentioned.

Response: Thank for your comment. GLI/PIB was reimbursed by the National Health Insurance of Taiwan since Aug 2018 for patients with confirmed HCV viremia without prior use of DAA. The treatment period was 8 weeks for patients without liver cirrhosis and 12 weeks for patients with compensated liver cirrhosis. The treatment period was 16 weeks for genotype 3 patients with prior interferon therapy

2\) The number of patients who have experienced treatment with DAAs should be described.

Response: Thank for your comment. In Taiwan, the use of DAA was restricted to licensed gastroenterologist and all the patients included treatment in the same department during the treatment period. Patients with resistance to DAA therapy would be referred to special hepatology center and thus, we include only treatment naïve patients in this study. We will acknowledge it as our study limitation.

3\) The relationship between death and treatment should be assessed.

Response: The cause of death was discussed in the discussion section in the revised manuscript. Two deaths occurred in the ESRD (n = 1) and non-ESRD (n = 1) groups, and both were super-elderly, 80 and 85 years old, respectively. Both patients died during sleep and had no signs of other systemic disease during the last phone contact. Cardiogenic cause of death was suspected and judged not to be related to the HCV treatment. The third patient died of chemotherapy related infection.

4\) The complications other than pruritus should be described.

Response: Thank for your comment. We add Table 3 to mention other complications associated with GLI/PIB therapy in the revised manuscript.
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PONE-D-20-18097R1

Glecaprevir--Pibrentasvir for Chronic Hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting

PLOS ONE

Dear Dr. Hsu-Heng Yen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 06 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Tatsuo Kanda, M.D., Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: (No Response)

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Because pruritus is common in dialysis patients, showing the prevalence of pruritus before treatment between groups will help to clearly understand the results of time course data in table 4.

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: No

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0237582.r004

Author response to Decision Letter 1

23 Jul 2020

Reviewer \#1: Because pruritus is common in dialysis patients, showing the prevalence of pruritus before treatment between groups will help to clearly understand the results of time course data in table 4.

Response: Thank for your comment. We believe this issue is important as the reviewer mentioned. The presence and the severity of pruritus at baseline is not a contra-indication for anti-HCV therapy in our real-world practice. As this is a retrospective real-world study, we didn't record the pruritus symptoms before treatment initially in our practice. As mentioned in the discussion, after encountering the first patient with premature GLE/PIB therapy discontinuation from this side effect, we learned the importance of providing proactive measures to educate our patients before initiating therapy and using medications such as antihistamine and/or topical agent to relieve pruritus symptom therapy initiation. Such measures have helped patients adhere to the GLE/PIB therapy in previous studies. We acknowledge this as a limitation of the present study in the revised manuscript.
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Glecaprevir--Pibrentasvir for Chronic Hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting

PLOS ONE

Dear Dr. Hsu-Heng Yen,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: 

1\) Authors should describe the definition of ESRD clearly.

==============================

Please submit your revised manuscript by Sep 10 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Tatsuo Kanda, M.D., Ph.D.

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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27 Jul 2020

Response to ACADEMIC EDITOR's comments

1\) Authors should describe the definition of ESRD clearly.

Response: Thank for your comment to improve the manuscript. In the present study, we define ESRD as CKD Stage 5D who received dialysis (Kanda T, et al. Hepatol Int. 2019;13(2):103-9. )
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Dear Dr. Hsu-Heng Yen,

We're pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you'll receive an e-mail detailing the required amendments. When these have been addressed, you'll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at <http://www.editorialmanager.com/pone/>, click the \'Update My Information\' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible \-- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

Kind regards,

Tatsuo Kanda, M.D., Ph.D.

Academic Editor

PLOS ONE
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Glecaprevir--Pibrentasvir for Chronic Hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting

Dear Dr. Yen:

I\'m pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

If we can help with anything else, please email us at <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Tatsuo Kanda

Academic Editor

PLOS ONE
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